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ABSTRACT		Neonatal	screening	is	a	vital	process	that	identifies	apparently	healthy	neonates	with	serious	inherited	dis-orders,	which	are	generally	metabolic	in	origin	and	correctable	by	dietary	or	drug	interventions.	Compre-hensive	screening	programs	for	congenital	diseases	of	newborn	infants	are	lacking	at	an	international	level.	This	article	will	review	the	challenges	involved	in	the	implementation	of	a	sustainable	program	of	new	born	screening.	 	 	
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INTRODUCTION	Inborn	errors	of	metabolism	are	rare	in	isolation,	but	collectively	are	common.	They	usually	present	in	the	neonatal	period	or	infancy,	but	can	occur	at	any	time,	even	in	adulthood	[1]	The	concept	of	screening	newborns	no	longer	refers	only	to	the	screening	tests	themselves	but	includes	all	of	 the	elements	essential	 for	every	neonate	 to	have	access	to	a	screening	system	that	is	optimal	in	terms	of	quality	and	performance	 [2].	 	Screening	programs	for	congenital	diseases	of	newborn	infants	have	been	in	effect	for	several	decades	in	some	countries.	More	than	30	diseases	can	be	screened	for	in	the	neonatal	period,	and	this	list	is	growing	[3–8].	There	are	ten	challenges	to	successfully	implement	a	sustainable	program	of	new	born	screening	
	
Planning		The	momentum	 is	 created	 through	 visionary	 ideas	that	can	be	molded	 into	a	systematic	approach	 to	a	sustainable	 national	 NDBS	 program.	 Once	 logically	developed,	 the	program	plan	provides	a	 foundation	on	which	 to	establish	 the	other	elements	necessary	for	success.	
Leadership		Successful	program	implementation	usually	requires	passionate	 leadership	(individual	or	group)	with	an	ability	 to	 understand	 and	 address.	 Leaders	 must	clearly	 convey	 ideas	 and	 successfully	motivate	 oth-ers.	The	initiation	of	a	new	program	or	new	ideas	usu-ally	 requires	 time,	 and	 leaders	 must	 be	 willing	 to	make	the	required	time	investment.	
Education		New	ideas	result	from	the	accumulation	and	transfer	of	 new	 knowledge.	 The	 education	 of	 professionals,	policymakers	 and	 the	public	must	be	provided	 in	 a	carefully	thought-out	way	that	addresses	stakeholder	concerns	 that	 may	 adversely	 affect	 successful	 pro-gram	implementation.	
Medical	support		For	a	new	or	expanded	medical	program,	such	as	pro-gram	of	new	born	screening:	to	succeed,	the	medical	community	 must	 accept	 it.	 Program	 leaders	 must	have	sufficient	knowledge	and	vision	to	address	med-ical	questions	in	a	manner	that	builds	confidence	and	collaboration	among	peers.	Successful	NDBS	requires	timely	 and	 appropriate	 diagnosis	 and	 treatment,	which	requires	the	cooperation	of	primary	care	and	specialty	healthcare	providers.	
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Technical	support		Because	 NDBS	 analytical	 protocols	 are	 micro-tech-niques	 that	 differ	 from	 routine	 medical	 laboratory	tests;	 implementation	 usually	 requires	 some	 tech-nical	training	and	knowledge	sharing.	Similarly,	spec-imen	collection	and	transport	as	well	as	the	post-an-alytical	 processes	 of	 result	 reporting	 and	 follow-up	(including	 clinical	 and	 laboratory	 confirmation)	are	essential	 pre-analytical	 processes	 that	 must	 be	properly	executed.	Analytical	technical	support	is	of-ten	 available	 from	 product	 vendors	 specializing	 in	NDBS,	 and	 pre-	 and	 post-analytical	 support	 can	 be	obtained	 from	 other	 more	 developed	 NDBS	 pro-grams.	
Logistical	support	Mechanisms	 must	 be	 developed	 for	 obtaining	 and	distributing	 blood	 collection	 supplies,	 training	 the	testing	and	follow-up	personnel,	transporting	speci-mens	to	the	screening	laboratory(ies),	providing	for	screening	 laboratory	 operations	 (equipment,	 sup-plies	and	maintenance),	maintaining	appropriate	rec-ords,	 and	 reporting	 the	 screening	 results	 quickly	while	addressing	cultural	and	other	sensitivities.	
Protocol/policy	development	Institutionalized	policies	and	protocols	addressing	all	NDBS	system	components	prevent	confusion	and	un-necessary	overlap.	Six	system	components	should	be	addressed:	education,	screening	(including	consider-ations	 of	 consent/dissent	 for	 testing,	 data	 sharing,	and	 residual	 specimen	 storage	 and	 use),	 follow-up/tracking,	diagnosis,			treatment/management,	and	evaluation/quality	 improvement.	 A	 comprehensive	listing	of	possible	program	elements	that	may	be	in-cluded	 in	 policy/	 protocol	 development	 [Program	Evaluation	and	Assessment	Scheme	(PEAS)]	has	been	published	and	may	provide	a	useful	planning	tool.		
Administration	Strong	leadership,	planning	and	policy	development	should	lead	to	efficient	and	effective	program	admin-istration/management.	 Successful	 patient	 outcomes	will	be	achieved	with	properly	functioning	program	components	and	timely	and	optimized	medical	man-agement.	 Good	 program	 administration	 should	 en-sure	 that	 improved	 newborn	 health	 is	 attainable	within	the	confines	of	the	healthcare	system.	
Evaluation	Outcome	monitoring	by	observation	of	disorder-spe-cific	sentinel	events	provides	a	means	for	program	of	new	 born	 screening	 evaluation	 and	 should	 be	 de-signed	 to	 assist	 with	 continuing	 program	 improve-ments.	Similarly,	indicators	of	the	successful	function	of	other	program	of	new	born	screening,	system	com-ponents,	 including	 external	 laboratory	 proficiency	testing,	 should	 be	 monitored	 as	 part	 of	 an	 overall	
quality	assurance	program.	The	PEAS	tool	noted	ear-lier	has	been	modified	for	this	purpose	in	at	least	one	NDBS	program.	
Sustainability	To	 become	 sustainable,	 the	 program	 of	 new	 born	screening	must	be	integrated	into	a	functioning	pub-lic	health	system	and	be	adequately	 financed.	Some	countries	have	been	successful	in	obtaining	approval	for	 financing	 through	 national	 public	 health	 insur-ance	programs,	but	this	process	is	often	slow	and	in-complete.	 As	 a	 result,	 other	 financing	 schemes,	 in-cluding	a	fee	system,	should	be	considered.	Many	de-veloped	programs	implore	a	system	in	which	birthing	facilities	 purchase	 screening	 kits	 (collection	 cards)	and	are	responsible	for	their	own	eimbursement.	In	such	cases,	care	must	be	taken	to	limit	the	adminis-trative/collection	charges	 that	may	be	added	 to	 the	test	cost	to	the	patient;	otherwise,	the	patient	charges	will	become	excessive	and	counterproductive.	When	fees	are	considered,	all	program	costs,	including	both	laboratory	 and	 non-laboratory	 screening	 elements	(i.e.,	program	administration,	equipment,	education,	public	 relations,	 follow-up,	 and	 specimen	 storage),	must	be	considered	[9].	Traditionally	 the	 inherited	metabolic	diseases	were	classified	as	disorders	of	•	 	Carbohydrate	metabolism,		•	 Amino	acid	metabolism,	•	 	Organic	acid	metabolism	or	lysosomal	stor-age	diseases.		In	recent	decades,	hundreds	of	new	inherited	disor-ders	of	metabolism	have	been	discovered	and	the	cat-egories	have	proliferated.	Following	are	some	of	the	major	classes	of	congenital	metabolic	diseases,	with	prominent	 examples	 of	 each	 class.	 Many	 others	 do	not	fall	into	these	categories.		
CONCLUSION	In	 the	outlook,	expanding	communication	 technolo-gies	will	likely	play	a	larger	role	in	educating	parents	and	 professionals	 regarding	 program	 of	 new	 born	screening.	In	developing	healthcare	systems,	commu-nication	 technologies	 should	 be	 particularly	 useful	for	data	and	result	transfer	and	for	improved	vendor	support	of	testing	equipment	and	other	supplies	crit-ical	 to	 the	 screening	 process.	 Strategic	 planning	 as	well	as	multi-national	collaborations	will	continue	to	be	 critical	 to	 sustainable	 program	 of	 new	 born	screening.	Necessary	information	for	policy	decisions	originate	from	data,	and	it	is	important	that	national	and	regional	data	be	standardized,	collected	centrally	and	periodically	analyzed.	Programs	should	be	aware	of	 developing	 international	 information	 technology	standards	and	definitions	such	that	they	may	be	con-sidered	during	planning	deliberations.	New	technol-ogies	 continue	 to	 be	 developed	 to	 result	 in	 an	 in-creased	number	of	screening	possibilities,	and	efforts	
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must	be	made	in	developing	programs	to	stay	abreast	of	 technological	 changes	 that	 may	 affect	 screening	protocols	and	policies[9].	
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